[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].

A triple combination therapy of simeprevir (SMV), pegylated-interferon and ribavirin (PR) was released to clinical practice in Japan on December of 2013, ahead of the rest of the world. This regimen is recommended for genotype 1 hepatitis C in AASLD, EASL and WHO guidelines based the data of phase III trials. CONCERTO-1, 2, 3, 4 were phase III trial in Japan investigated efficacy and safety of simeprevir once daily with peginterferon α2a or α2b/ribavirin combination therapy in treatment-naïve and treatment-experienced patients with genotype 1 HCV infection. SMIV/PR combination therapy provided high sustained virologic response rate 12 weeks after treatment end in both treatment-naïve and treatment-experienced patients with a 24-week treatment duration.